Neisseria Meningitidis

An investigational pentavalent vaccine for Neisseria meningitidis showed promise in a phase 2 trial conducted among toddlers in Mali, researchers reported in The New England Journal of Medicine.

CDC data show that cases of meningococcal disease caused by serogroup B in the United States is at an all-time low — only 0.11 cases per 100,000 people in 2017.

The overall incidence of meningococcal disease is low among college students in the United States, but they were over three times more likely to develop meningococcal B disease, or MenB, compared with those who did not attend college, according to research published in Pediatrics. The increased risk for disease among this population highlights the importance of vaccination, researchers said.